Leveraging Digitalization To Resolve Cell And Gene Therapy Manufacturing Challenges

In life sciences, where speed to market is the definition of competitive advantage, today’s automation investments are decidedly modular, whether in the context of plant, process, or production.

Once the first cell therapy was approved by the U.S. Food and Drug Administration (FDA) in 2017, manufacturers that were producing conventional products were incentivized to shift to precision medicine, but it has become evident that traditional processes and protocols cannot keep pace as demand continues to grow. To meet the escalating need for precision medicines, the manufacturing process must be streamlined to enable rapid, reliable production, and digitalization is the key to accomplishing this goal.

Read the whitepaper to learn more about how cell and gene therapy manufacturers are leveraging digitalization to resolve manufacturing challenges.